Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer

Gastric Cancer

Volumn 17, Issue 4, 2014, Pages 718-724

  Di Lauro, Luigi ^a   Vici, Patrizia ^a   Belli, Franca ^b   Tomao, Silverio ^c   Fattoruso, Silvia Ileana ^d   Arena, Maria Grazia ^e   Pizzuti, Laura ^a   Giannarelli, Diana ^a   Paoletti, Giancarlo ^a   Barba, Maddalena ^a   Sergi, Domenico ^a   Maugeri Saccà, Marcello ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Italian Charcot Marie Tooth Association (AICMT) Clinic   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Division of Oncology Fiorini Hospital   (Italy)

^e Toraldo Hospital   (Italy)

Author keywords

Capecitabine; Docetaxel; Gastric cancer; Oxaliplatin; Phase II

Indexed keywords

ANTIEMETIC AGENT; CAPECITABINE; CORTICOSTEROID; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; PLATINUM COMPLEX; TAXOID;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LOWER ESOPHAGUS SPHINCTER; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PROGRESSION FREE SURVIVAL; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84911425630     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-013-0321-3     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev. 2013;39:60–7.
3. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–8.
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer (Phila). 1993;72:37–41.
5. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587–91.
6. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.
7. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
8. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, V325 Study Group, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.
9. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.
10. Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14:50–5.
11. Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer. 2009;12:132–41.
12. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, ToGA Trial Investigators, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
13. Chen XL, Chen XZ, Yang C, Liao YB, Li H, Wang L, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e60320.
14. Bang YJ. Capecitabine in gastric cancer. Expert Rev Anticancer Ther. 2011;11:1791–806.
15. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Arbeitsgemeinschaft Internistische Onkologie, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435–42.
16. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–73.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.
18. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer (Phila). 2010;116:1446–53.
19. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Australasian Gastro-Intestinal Trials Group, et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010;102:475–81.
20. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19:1882–7.
21. Pernot S, Mitry E, Samalin E, Dahan L, Dalban C, Ychou M, et al. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Gastric Cancer. 2013. doi:10.1007/s10120-013-0266-6.
22. Van Cutsem E, Boni C, Tabernero J, Massuti B, Richards DA, Prenen H, et al. Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. J Clin Oncol 2011;29(suppl): abstr 4018
23. Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, et al. Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol. 2008;61:623–9.
24. Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH, et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy. 2010;56:94–100.
25. Yang T, Shen X, Tang X, Wei G, Zhang H, Du C, et al. Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer. Tumori. 2011;97:466–72.
26. Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012;48:518–26.
27. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11:136–46.
28. Liang H, Kim YH. Identifying molecular drivers of gastric cancer through next-generation sequencing. Cancer Lett. 2012. doi:10.1016/j.canlet.2012.11.029 (Epub ahead of print).
29. Kim R, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: is there a standard approach? Crit Rev Oncol Hematol. 2013. doi:10.1016/j.critrevonc.2013.05.007 (Epub ahead of print).
30. Goel G, Jauhri M, Negi A, Aggarwal S. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. Hematol Oncol Stem Cell Ther. 2010;3:55–9.
31. Amarantidis K, Xenidis N, Chelis L, Chamalidou E, Dimopoulos P, Michailidis P, et al. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer. Oncology. 2011;80:359–65.
32. Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, et al. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. Acta Oncol. 2013. doi:10.3109/284186X.2013.833346.
33. Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol. 2010;28:3945–50.
34. Schønnemann KR, Jensen HA, Yilmaz M, Jensen BY, Larsen O, Pfeiffer P. Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer. Br J Cancer. 2008;99:858–61.
35. Di Lauro L, Giacinti L, Arena MG, Sergi D, Fattoruso SI, Giannarelli D, Lopez M. Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. J Exp Clin Cancer Res. 2009;28:34.
36. Hejna M, Raderer M, Zacherl J, Ba-Ssalamah A, Püspök A, Schmidinger M, et al. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001. Anticancer Drugs. 2008;19:535–9.
37. Neri B, Pantaleo P, Giommoni E, Grifoni R, Paoletti C, Rotella V, et al. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer. 2007;96:1043–6.